Horizon 2020 Framework Programme for Research and Innovation (2014-2020)
The consortium name ‘MultipleMS’ refers to the disease Multiple Sclerosis, the multiple manifestations thereof and to the size and multiplicity of the partnership.
A large global new partnership called ‘MultipleMS’, coordinated by 'Karolinska Institutet' in Sweden, has been awarded 15 million euro from the European Commission in the Horizon2020 program to find novel and better treatments for Multiple Sclerosis (MS). In this project, universities and companies across 11 European countries and the US will unite efforts to tailor the development and application of therapies to the individual MS patient.
Project leader professor Ingrid Kockum (Karolinska Institutet, Sweden) about why MultipleMS is important:
“I am excited about the MultipleMS project since I think that we will be able to address research questions that we have not been able to address efficiently previously through collaboration between researchers with unique experiences and because we are utilizing data from different fields in joint analyses.
I am motivated to carry out this project because I believe that it will result in real progress in understanding aspects of Multiple Sclerosis pathogenesis which can be used for improvement of treatment of Multiple Sclerosis.”
MultipleMS becomes member of the IHEC consortium
MultipleMS will in part rely on the large amount of work that was performed by the IHEC consortium. During the last meeting of the IHEC consortium MultipleMS was accepted as member of this ongoing consortium. Furthermore, MultipleMS participants Chris Cotsapas and Stephan Beck now serve as International Scientific Steering Committee members of the IHEC consortium.
Global partnership launched to enable personalized therapies in multiple sclerosis
MS is an immune-mediated disease and a leading cause of non-traumatic disability in young adults in Europe, affecting over 2 million persons worldwide. MS is a highly heterogeneous disease and a cure for MS is not yet available. As the result of current treatments varies strongly from patient to patient, predicting the specific beneficial treatment for each patient would improve disease management.
“What is truly unique about this project is the scale of the partnership and the huge amount and different kinds of patient data that will be combined. Our novel approach is to take the multifaceted nature of MS as the starting point for identifying personalized treatment opportunities in MS”, Professor Ingrid Kockum of KI, coordinator of the project, stated.
The project builds on the foundations and research networks laid out by earlier consortia such as the Nordic MS genetics network, the International MS Genetics Consortium (IMSGC) and International Human Epigenome Consortium (IHEC).
“The project will combine a variety of data, such as, clinical, genetic, epigenetic, molecular, MRI and lifestyle data from more than 50,000 MS patients and 30,000 healthy individuals to elucidate differential disease characteristics in patients”, Professor Kockum says.
In parallel with the integration of the collectively available data, a sample of newly diagnosed patients will be followed longitudinally, resulting in a harmonized cohort to verify the lead findings. Based on this integrated information, the aim is that both existing and new treatments can be personalized based on characteristics and biomarkers in individual patients.